Several experimental studies in murine models of sepsis have pointed to a key role for GM-CSF in increasing survival, and therefore GM-CSF has also been tested as an immunostimulating adjuvant therapy in patients with sepsis. This evidence concerns the gene CSF2 and Sepsis.